Upload
muscletech-network
View
740
Download
0
Embed Size (px)
DESCRIPTION
RCT in stem cells. From theory to practice
Citation preview
HOSPITAL CLÍNIC VETERINARI
RCT in stem cells From theory to prac4ce
MSC RESEARCH 2013
DISC
Ovine P. NERVE
Aastrom
IBGM
Ovine CARTILAGE
Pseudoarthrosis
Osteonecrosis
Maxilar
Equine CARTILAGE
Pseudoarthrosis clinical trials
Pseudoarthrosis PEi
PEi Salvat - Histocell
Aastrom
Aastrom
Aastrom
BONE 05-048
BST
BST
BST
BST
PEi 10-134
OA II-‐III°
OA II-‐IV°
BST PEi
OA II-‐IV° crio
OA II-‐IV° alo vs hialur.
IBGM
IBGM
IBGM
10-005
OA II-‐IV° (MSC vs PRP)
CARTILAGE
animal model
Equine tendon
Ensayo clínico I-‐II
ONT
preclínica BPL
Procedimiento Centralizado
Cláusula Exclusión
Ensayo clínico III
OCATT AEMPS
protocolo
CEICs
Laboratorio GMP
Hospital
PEi
CRO
Promotor
inves4gadores RD 2043/94
RD 1369/2000
Gestora
Uso Compasivo EMA
Financiación
RD 223/2004 Ley 29/2006
RD 1344/2007
Ley 14/2007
RD1825/2009 RD 1301/2006
Advanced Therapy
characterized
accurate dose
presentation
Medicines Agency control
phenotype
immunophenotype
plastic adherence
presentation
osteocito
condrocito
miocito
c. estroma
tenocito
adipocito
dexametasona indometacina
isobutilmetilxilina
dexametasona ácido ascórbico
TGF-β
MSC
in vitro
• Osiris Therapeutics
glucocorticoides 5% suero equino
pluripotency
1 w 2 w 3 w
degeneration inflammation
regeneration fibrosis
muscle repair timing Time Factor
Dose Factor
BM or AT harvest
crio preserved intermediate product
therapeutic dose
Cell Therapy
cellular pre plating expantion cells
10 days
RICES
BM or AT allogenic
crio preserved intermediate product
therapeutic dose
Cell Therapy
cellular pre plating expantion cells
10 days
RICES
A
1 w 2 w 3 w
degeneration inflammation
regeneration fibrosis
muscle repair timing Time Factor
Dose Factor
osteocito
condrocito
miocito
c. estroma
tenocito
adipocito
MSC
in vitro
• Osiris Therapeutics
BM-‐MSC 6 AT-‐MSC 6
SF
prp
12 equinos lesión SDTF 20x10E6 MSC
manguito rotadores 20x10E6 MSC + membrana Hospital Universitario San Carlos. Madrid
epicondilitis 1x10E6 vs 10x10E6 allo-AT MSC
Conclusiones
Terapia celular con MSC (dosis: 15x10E6 a 40x10E6)
§ Viable § Segura § Indicios de eficacia § Actual: Solo bajo ensayo o UC § Control Agencia Medicamento
HOSPITAL CLÍNIC VETERINARI
RCT in stem cells From theory to prac4ce